Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways
- PMID: 32774810
- PMCID: PMC7395184
- DOI: 10.22038/ijbms.2020.43016.10115
Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways
Abstract
Objectives: Chemotherapies used to treat colon cancer might often fail due to the emergence of chemoresistance and side effects. Escherichia coli Nissle 1917 (EcN) is a beneficial probiotic, whose molecular mechanisms in the prevention of colon cancer are yet to be fully understood. The present study assessed the anti-cancer effects of EcN treatments in human colorectal cancer, HT-29 cell line, with the analysis of related mechanisms.
Materials and methods: The co-culture conditioned-media (CM) of EcN with adenocarcinoma HT-29 cells and heat-inactivated bacteria (HIB) were applied for the treatment of the HT-29 cells. To study the inhibition potential of CM and HIB on cancer cells, various cellular/molecular analyses were implemented, including DAPI-staining and DNA ladder assays, flow cytometry and Real-time quantitative PCR (qPCR), as well as Western blotting analyses.
Results: Our results indicated that EcN could elicit apoptotic impacts on the colon cancer HT-29 cells by up-regulating PTEN and Bax and down-regulating AKT1 and Bcl-xL genes.
Conclusion: Based on our findings, EcN is proposed as a useful supplemental probiotic treatment against colon cancer.
Keywords: AKT; Apoptosis; Cell signaling; Colon cancer; Escherichia coli Nissle1917.
Figures






Similar articles
-
Leuconostoc mesenteroides-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways.Biomed Pharmacother. 2017 Oct;94:1094-1100. doi: 10.1016/j.biopha.2017.08.033. Epub 2017 Aug 16. Biomed Pharmacother. 2017. PMID: 28821160
-
Immuno-modulatory effect of probiotic E. coli Nissle 1917 in polarized human colonic cells against Campylobacter jejuni infection.Gut Microbes. 2021 Jan-Dec;13(1):1-16. doi: 10.1080/19490976.2020.1857514. Gut Microbes. 2021. PMID: 33382951 Free PMC article.
-
Probiotic Escherichia coli Nissle 1917 reduces growth, Shiga toxin expression, release and thus cytotoxicity of enterohemorrhagic Escherichia coli.Int J Med Microbiol. 2015 Jan;305(1):20-6. doi: 10.1016/j.ijmm.2014.10.003. Epub 2014 Oct 27. Int J Med Microbiol. 2015. PMID: 25465158
-
Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application.Appl Microbiol Biotechnol. 2016 Oct;100(20):8693-9. doi: 10.1007/s00253-016-7829-5. Epub 2016 Sep 17. Appl Microbiol Biotechnol. 2016. PMID: 27640192 Review.
-
[The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases].Postepy Hig Med Dosw (Online). 2014 Nov 6;68:1251-6. doi: 10.5604/17322693.1127882. Postepy Hig Med Dosw (Online). 2014. PMID: 25380207 Review. Polish.
Cited by
-
Inulin impacts tumorigenesis promotion by colibactin-producing Escherichia coli in ApcMin/+ mice.Front Microbiol. 2023 Feb 2;14:1067505. doi: 10.3389/fmicb.2023.1067505. eCollection 2023. Front Microbiol. 2023. PMID: 36819017 Free PMC article.
-
Unveiling the Interplay Between the Human Microbiome and Gastric Cancer: A Review of the Complex Relationships and Therapeutic Avenues.Cancers (Basel). 2025 Jan 12;17(2):226. doi: 10.3390/cancers17020226. Cancers (Basel). 2025. PMID: 39858007 Free PMC article. Review.
-
Deletion of the cheZ gene results in the loss of swimming ability and the decrease of adhesion ability to Caco-2 cells in Escherichia coli Nissle 1917.Folia Microbiol (Praha). 2023 Jun;68(3):395-402. doi: 10.1007/s12223-022-01019-7. Epub 2022 Nov 25. Folia Microbiol (Praha). 2023. PMID: 36434260
-
Gut microbiota resilience and recovery after anticancer chemotherapy.Microbiome Res Rep. 2023 May 6;2(3):16. doi: 10.20517/mrr.2022.23. eCollection 2023. Microbiome Res Rep. 2023. PMID: 38046820 Free PMC article. Review.
-
Intratumoral microorganisms in tumors of the digestive system.Cell Commun Signal. 2024 Jan 25;22(1):69. doi: 10.1186/s12964-023-01425-5. Cell Commun Signal. 2024. PMID: 38273292 Free PMC article. Review.
References
-
- Khiavi MA, Safary A, Aghanejad A, Barar J, Rasta SH, Golchin A, et al. Enzyme-conjugated gold nanoparticles for combined enzyme and photothermal therapy of colon cancer cells. Colloids Surf. A Physicochem Eng Asp. 2019;572:333–344.
-
- Vahed SZ, Barzegari A, Saadat YR, Goreyshi A, Omidi Y. Leuconostoc mesenteroides-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways. Biomed Pharmacother. 2017;94:1094–1100. - PubMed
-
- Salmanzadeh R, Eskandani M, Mokhtarzadeh A, Vandghanooni S, Ilghami R, Maleki H, et al. Propyl gallate (PG) and tert-butylhydroquinone (TBHQ) may alter the potential anti-cancer behavior of probiotics. Food Biosci. 2018;24:37–45.
-
- Schultz M. Clinical use of E. coli Nissle. 1917 in;14:1012–1018. - PubMed
-
- Jafari B, Rezaie A, Alizadeh S. Isolation and identification of potentially probiotic bacteria from traditional dairy products of Ardabil region in Iran. Ann Biol Res. 2011;2:311–317.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous